Ubs Group Ag Viridian Therapeutics, Inc.\De Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Ubs Group Ag holds 504,185 shares of VRDN stock, worth $7.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

504,185

Previous 512,071 1.54%

Holding current value

$7.3 Million

Previous $9.82 Million 30.77%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$13.48 - $20.91 $106,303 - $164,896	-7,886 Reduced 1.54%	504,185 $6.8 Million
Q4 2024 Feb 14, 2025	BUY	$17.85 - $25.71 $7.63 Million - $11 Million	427,338 Added 504.33%	512,071 $9.82 Million
Q3 2024 Nov 14, 2024	SELL	$12.16 - $23.33 $1.77 Million - $3.4 Million	-145,643 Reduced 63.22%	84,733 $1.93 Million
Q2 2024 Aug 13, 2024	SELL	$11.6 - $17.26 $1.73 Million - $2.58 Million	-149,208 Reduced 39.31%	230,376 $3 Million
Q1 2024 May 13, 2024	BUY	$17.09 - $23.82 $4.04 Million - $5.63 Million	236,198 Added 164.73%	379,584 $6.65 Million
Q4 2023 Feb 09, 2024	BUY	$11.12 - $22.5 $833,666 - $1.69 Million	74,970 Added 109.58%	143,386 $3.12 Million
Q3 2023 Nov 09, 2023	SELL	$15.16 - $24.7 $169,261 - $275,775	-11,165 Reduced 14.03%	68,416 $1.05 Million
Q2 2023 Aug 11, 2023	BUY	$22.57 - $29.67 $243,530 - $320,139	10,790 Added 15.69%	79,581 $1.89 Million
Q1 2023 May 12, 2023	SELL	$25.04 - $37.6 $1.93 Million - $2.89 Million	-76,987 Reduced 52.81%	68,791 $1.75 Million
Q4 2022 Feb 08, 2023	BUY	$18.78 - $29.74 $1.81 Million - $2.87 Million	96,481 Added 195.71%	145,778 $4.26 Million
Q3 2022 Nov 10, 2022	BUY	$10.7 - $25.5 $527,338 - $1.26 Million	49,284 Added 379107.69%	49,297 $1.01 Million
Q2 2022 Aug 10, 2022	SELL	$9.55 - $19.0 $1,995 - $3,971	-209 Reduced 94.14%	13 $0
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $3,509 - $4,363	209 Added 1607.69%	222 $4,000
Q4 2021 Feb 14, 2022	SELL	$15.65 - $21.5 $22,379 - $30,745	-1,430 Reduced 99.1%	13 $0
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $15,286 - $26,026	1,430 Added 11000.0%	1,443 $24,000
Q1 2021 May 12, 2021	BUY	$15.5 - $24.93 $201 - $324	13 New	13 $0

Others Institutions Holding VRDN

# of Institutions

189

Shares Held

79.6M

Call Options Held

92.2K

Put Options Held

55.2K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $577M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account